Cargando…

Real world evidence of long-term benefits from allergen-specific immunotherapy (AIT)

Detalles Bibliográficos
Autor principal:	Scadding, Guy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672030/ https://www.ncbi.nlm.nih.gov/pubmed/34950925 http://dx.doi.org/10.1016/j.lanepe.2021.100283

Ejemplares similares

Allergen Immunotherapy (AIT): a prototype of Precision Medicine
por: Canonica, GW, et al.
Publicado: (2015)

AIT (allergen immunotherapy): a model for the “precision medicine”
por: Passalacqua, Giovanni, et al.
Publicado: (2015)

Physicians' attitude to allergen immunotherapy (AIT) prescription: an Italian survey
por: Modiano, Ambra
Publicado: (2015)

Duration of Allergen Immunotherapy for Long-Term Efficacy in Allergic Rhinoconjunctivitis
por: Penagos, Martin, et al.
Publicado: (2018)

Vitamin D Role in Childhood Mite Allergy and Allergen Immunotherapy (AIT)
por: Petrarca, Claudia, et al.
Publicado: (2023)

Real-world use of nirmatrelvir–ritonavir: who benefits?
por: Molina, Kyle C, et al.
Publicado: (2023)

Real‐world evidence for the long‐term effect of allergen immunotherapy: Current status on database‐derived European studies
por: Vogelberg, Christian, et al.
Publicado: (2022)

Allergen Immunotherapy (AIT) in children: a vulnerable population with its own rights and legislation – summary of EMA-initiated multi-stakeholder meeting on Allergen Immunotherapy (AIT) for children, held at Paul-Ehrlich-Institut, Langen, Germany, 16.1.2019
por: Mahler, V., et al.
Publicado: (2020)

Real‐world benefits of allergen immunotherapy for birch pollen‐associated allergic rhinitis and asthma
por: Wahn, Ulrich, et al.
Publicado: (2018)

Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit -the centenary of allergen specific subcutaneous immunotherapy
por: Jacobsen, Lars, et al.
Publicado: (2012)

Real World Evidence: methodological issues and opportunities from the European Health Data Space
por: Kympouropoulos, Stelios
Publicado: (2023)

Real-world evidence for prehospital COVID-19 treatment in systemic autoimmune rheumatic disease
por: Bechman, Katie, et al.
Publicado: (2023)

Long-term benefit after allergen immunotherapy to HDM in elderly patients with allergic rhinitis
por: Bożek, Andrzej, et al.
Publicado: (2023)

Efficacy of Allergen Immunotherapy for Allergic Asthma in Real World Practice
por: Rhyou, Hyo-In, et al.
Publicado: (2019)

Long-term efficacy of allergen specific immunotherapy in atopic dermatitis patients
por: Wyrzykowska, Nina, et al.
Publicado: (2015)

Shared Decision-Making in Allergen Immunotherapy (AIT) Options Using a Questionnaire for Respiratory Allergic Patients: A Delphi Consensus Study
por: Antón, Mónica, et al.
Publicado: (2023)

Long-term effects of allergen sublingual immunotherapy
por: Bozek, Andrzej, et al.
Publicado: (2019)

COVID-19 outbreaks in acute and long-term care: Conceptualizing patterns of vulnerability and benefits of interventions
por: Andrew, Melissa K., et al.
Publicado: (2022)

Late Local Urticaria as a Long-term Sequela of Allergen-Specific Immunotherapy
por: Choi, Inseon S, et al.
Publicado: (2004)

Evaluating COVID-19 vaccines in the real world
por: Mills, Edward J, et al.
Publicado: (2022)

Allergen-specific immunotherapy
por: Moote, William, et al.
Publicado: (2011)

Allergen-specific immunotherapy
por: Moote, William, et al.
Publicado: (2018)

From Data to Wisdom: Biomedical Knowledge Graphs for Real-World Data Insights
por: Hänsel, Katrin, et al.
Publicado: (2023)

What prevents us from reusing medical real-world data in research
por: Gehrmann, Julia, et al.
Publicado: (2023)

Towards evidence-based response criteria for cancer immunotherapy
por: Garralda, Elena, et al.
Publicado: (2023)

Real-world effectiveness of oral antivirals for COVID-19
por: Burdet, Charles, et al.
Publicado: (2022)

Long-term Benefits of Risk Factor Reduction in Takotsubo Cardiomyopathy.—A Comment on Khalighi et al. Entitled “Takotsubo Cardiomyopathy: A Long Term Follow-up Shows Benefit with Risk Factor Reduction”, J. Cardiovasc. Dev. Dis., 2015, 2, 273–281.
por: Ponamgi, Shiva P., et al.
Publicado: (2016)

Allergen Peptides, Recombinant Allergens and Hypoallergens for Allergen-Specific Immunotherapy
por: Marth, Katharina, et al.
Publicado: (2014)

Preventing disease progression in multiple sclerosis—insights from large real-world cohorts
por: Engel, Sinah, et al.
Publicado: (2022)

Systemic reactions to subcutaneous allergen immunotherapy: real-world cause and effect modelling
por: Aue, Adam, et al.
Publicado: (2021)

Naturalizing psychopathology—towards a quantitative real-world psychiatry
por: Lahnakoski, Juha M., et al.
Publicado: (2021)

Patient preferences in allergy immunotherapy (AIT) in Germany – a discrete-choice-experiment
por: Damm, Kathrin, et al.
Publicado: (2016)

Vaccination prevents hospitalisations of children and adolescents. A real-world analysis
por: Bolcatto, Pablo G.
Publicado: (2022)

Mechanisms of allergen-specific immunotherapy
por: Fujita, Hiroyuki, et al.
Publicado: (2012)

Allergen-Specific Immunotherapy in Asthma
por: Jutel, Marek
Publicado: (2014)

Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens
por: Akdis, Cezmi A, et al.
Publicado: (2015)

Persistence in allergen immunotherapy: A longitudinal, prescription data‐based real‐world analysis
por: Pfaar, Oliver, et al.
Publicado: (2023)

P85 - Asthmatic children and adolescents treated in daily medical practice – results from a 2-year sublingual allergen immunotherapy (AIT) study with grass pollen tablets
por: Karagiannis, Efstrathios, et al.
Publicado: (2014)

Allergens, germs and asthma
por: Scadding, Glenis Kathleen
Publicado: (2015)

Symptom study app provides real-world data on COVID-19 vaccines
por: Drury, Ruth E, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_emi236e38bk3fgouo0d4qn4ceq